Eli Lilly has partnered with Insilico Medicine in a significant AI-driven drug discovery collaboration valued at up to $2.75 billion. The agreement provides Lilly with exclusive rights to develop a portfolio of novel oral therapeutics, leveraging Insilico’s generative AI platforms while combining their clinical expertise. The deal includes an upfront payment of $115 million and potential milestone bonuses, reflecting a growing industry trend towards using AI to enhance drug discovery efficiency and success rates. This partnership aims to tackle complex health challenges through innovative therapeutic solutions.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://pulse2.com/insilico-medicine-2-75-billion-ai-drug-discovery-collaboration-with-eli-lilly/
